Pacific Biosciences of California, Inc. (PACB) by event type
PACB moves most on coverage initiations — a median of +1.02% at 30 minutes across 18 measured events. Each row is measured over the last three years and read against the price at its own news timestamp. Back to the PACB overview →
How PACB reacts across 5 measured event types.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades 2,553 of 2,717 | 24 | -0.83% | 21% | -1.69% |
| Analyst downgrades 2,034 of 2,603 | 13 | -0.33% | 39% | +3.55% |
| Coverage initiations 151 of 2,283 | 18 | +1.02% | 56% | +5.84% |
| Rating reiterations 2,333 of 3,522 | 45 | -0.06% | 42% | +0.47% |
| Price-target cuts 121 of 1,527 | 23 | +0.31% | 65% | 0.00% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The rank under each event type orders every name measured for it by median 30-min reaction, most positive first — so a low rank on a downgrade means this name falls harder than most, not that it moves less. Names with an identical median share a rank; a name the cross-section does not carry shows no rank rather than a guessed one. 1 further class was observed with fewer than 10 measured events and is not published.
That’s how PACB usually reacts — get an email when it moves on news →Every name measured for these event types: Analyst upgrades → · Analyst downgrades → · Coverage initiations → · Rating reiterations → · Price-target cuts → · PACB overview →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| BOVIE MEDICAL (BVX) | 441 | 0.00% | 46% |
| Catalyst Pharmaceuticals, Inc. (CPRX) | 441 | 0.00% | 50% |
| EyePoint, Inc. (EYPT) | 439 | -0.25% | 46% |
| Abeona Therapeutics Inc. (ABEO) | 438 | +0.09% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.